Immunophotonics
Pharmaceuticals, 4340 Duncan Ave, St. Louis, Missouri, 63110, United States, 11-50 Employees
Phone Number: 31********
Who is IMMUNOPHOTONICS
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently devel...
Read More
- Headquarters: 4340 Duncan Ave, St. Louis, Missouri, 63110, United States
- Date Founded: 2012
- Employees: 11-50
- Revenue: $5 Million to $10 Million
- Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 8011
Does something look wrong? Fix it. | View contact records from IMMUNOPHOTONICS
Immunophotonics Org Chart and Mapping
Theresa Visarius
Vice President Business Development (Immunophotonics, Inc.) Managing Director (Ips Biopharma Ag)
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Immunophotonics
Answer: Immunophotonics's headquarters are located at 4340 Duncan Ave, St. Louis, Missouri, 63110, United States
Answer: Immunophotonics's phone number is 31********
Answer: Immunophotonics's official website is https://immunophotonics.com
Answer: Immunophotonics's revenue is $5 Million to $10 Million
Answer: Immunophotonics's SIC: 8011
Answer: Immunophotonics has 11-50 employees
Answer: Immunophotonics is in Pharmaceuticals
Answer: Immunophotonics contact info: Phone number: 31******** Website: https://immunophotonics.com
Answer: Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month